anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Before the start of the study, the Kron Technique and IAP measurement with a digital manometer were demonstrated both didactically and practically to 4th year Emergency Medicine residents. It was ensured that any two of these residents were continuously present on the monthly duty roster. When a patient who met the inclusion criteria presented to the emergency department, the residents were separately invited to the bedside for measurements by the attending physician without each other's knowledge. After the attending physician obtained information about the patient, the exclusion criteria were evaluated. After the patient was deemed eligible, the attending physician explained the application and the study to the patient in detail. Informed consent was obtained from the patients both verbally and in written. Demographic information (age, gender) and medical history were recorded.

Measurements were performed with the patient in the supine position. A transurethral Foley catheter (16 Fr) was inserted by the attending physician under sterile conditions. First, IAP was measured using the 'Kron technique.' The connection hose of the urine collection container was attached to the Foley catheter. The hose was clamped after the urine in the bladder was completely emptied. A sterile three-way tap was attached to the urine sample port in the connection hose. From the three-way tap, 25 ml of sterile saline was injected into the bladder with a syringe. Subsequently, one end of the transducer interconnection cable was connected to the three-way tap, and the other end was connected to the bedside monitor (GE B40 V3 bedside monitor, Germany). Subsequently, pressure adjustments were reset on the monitor, and IAP was recorded in mmHg. After this measurement, a digital manometer was used. This measurement was performed by the second resident. The "Compass Lumbar Puncture Pressure Transducer" (Mirador Biomedical, Seattle, WA, USA) was used as a digital manometer (Figure 2). After the bladder was completely emptied, the catheter was clamped again. 25 cc of sterile saline was injected into the bladder through the urine sample port. The digital manometer was connected to the urine sample port. The IAP value in cmH2O on the digital screen of the device was noted. The IAP measurement value recorded in cmH2O was converted to mmHg using the equation "1 cmH2O = 0.7355 mmHg." During the measurements, the patient's treatment plan was not interrupted.
The invention relates to the use of a novel vaccine antigen which is used preventively or therapeutically against diseases of bacterial, viral, cancerous or other origin.  The technical aim of the invention is to develop formulations that can increase the protective spectrum of existing vaccines and extend same against different pathogens.  For said purpose, protein NMB1125 was isolated and identified as a component of Neisseria meningitidis outer membrane preparations, which can induce bactericide activity.  In addition, the gene coding for protein NMB1125 was cloned and expressed, said protein being purified, and the immunogenicity thereof in animal biomodels was subsequently evaluated.  The high conservation level of the sequencing of homologous genes demonstrated the high value thereof as an antigen that induces a cross immune response when presented in different ways.  The resulting formulations are suitable for use in the pharmaceutical industry as vaccine formulations for human use.
The invention discloses an externally applied paste for the treatment of burns and scalds, which is prepared by the pharmaceutical raw materials with the following mixing ratio by weight: 4 to 8 percent borneol, 4 to 8 percent rhubarb, 8 to 12 percent bletilla striata, 8 to 12 percent roasted gypsum, 8 to 12 percent argy wormwood leaf ash and 50 to 60 percent lard. All the pharmaceutical raw materials of the externally applied paste for the treatment of the burns and the scalds are compatible, thus having the effects of clearing heat, removing toxicity, extracting toxicity, generating muscle,relieving swelling and stopping pain. The paste of the invention can stop the pain by only one usage. Furthermore, the paste can promote the wound healing, have the significant efficacy for the treatment of infection and purulent burns and scalds and be conductive to the promotion of the tissue recovery. The paste has no scars after the concrescence of the wound of a patient with deep II degree burns and scalds, the sweat glands and the sebaceous glands are smooth at the same time. The usage of the drug can allow the granulation tissues and the epithelial tissues to grow rapidly, cover the wound without the need of skin grafting and have no scars after the concrescence of the wound for the patient with III degree burns and scalds. The externally applied paste of the invention has the advantages of short course of treatment, fast efficacy, pure traditional Chinese medicine preparation, no toxicity or side effects, no scars, and good analgesic effect. The cure rate achieves 98 percent and the effective rate achieves 100 percent.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention refers to pharmacology, namely to creation of a new inter- and intra- multilayer vesicular composition containing a drug dithranol used for psoriasis treatment. A controlled release vesicular composition used for drug delivery containing a set of dispersed concentric two-layer vesicles with an external layer enclosing an aqueous hydrocolloid gelling agent, and an internal layer being a lipid phase. Both layers have a drug dispersed in the concentration 70-80% in the internal layer and 20-30% in the external layer. Particularly, the composition contains as follows, %: dithranol 0.25-1.0; phospholipid 8-12; cholesterol 3-7; butylated hydroxytoluol 0.1-0.5; hydrocolloid gelling agent 0.5-3.0; a phosphate salt buffer - the rest. The average vesicle size in the composition varies in the range 1-10 micron. The hydrocolloid gelling agent possesses thixotropic rheological characteristic and particularly represents methyl cellulose. Besides the invention concerns application of said composition for drug delivery for treatment of dermal problems, particularly psoriasis. The invention improves efficiency of molecules of the drug in a reduced dose, makes the composition more acceptable with relation to rheology, and stable, provides the absence of irritation and stains formation, is easily applied (remains on an injured area). The declared composition can contain the increased amount of the drug without irritation and stains formation when severity of disease requires increased doses. ^ EFFECT: product is characterised by improved therapeutic properties of dithranol combined with some other favourable properties. ^ 6 cl, 1 ex
NEW MATERIAL:A fraction separated from a cultured product of a mold belonging to Monascus genus and having the following physical and chemical properties. Column chromatography, eluted at the eluting position of a neutral amino acid standard when adsorbed to a strongly acidic cation exchange resin column equilibrated with 0.2M pyridine-acetic acid buffer solution of 3.1 pH and eluted with 0.4M pyridine-acetic acid buffer solution of 4.6 pH; solubility, soluble in water, methanol, acetone, etc., and insoluble in n-butanol, chloroform, etc.; nature and appearance, highly viscous liquid having brown color; molecular weight, <=3,000 by gel-filtration; color reaction, positive to ninhydrin reaction and Folin reaction. USE:A hypotensor. PREPARATION:For example, Monascus pilosus (IFO 4520) is inoculated in steamed rice, cultured and dried to obtain monascus. The monascus is extracted with ethanol, the extract is dissolved in 28% aqueous solution of acetic acid and the solution is passed through a strongly acidic cation exchange resin column. The adsorbed component is eluted to obtain the objective novel fraction.
Amlodipine and benazepril hydrochloride can cause symptomatic hypotension, sometimes complicated by oliguria, progressive azotemia, acute renal failure, or death. Symptomatic hypotension is most likely to occur in patients who have heart failure, severe aortic or mitral stenosis, obstructive hypertrophic cardiomyopathy or have been volume or salt depleted as a result of diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. Correct volume and salt depletion before starting therapy with benazepril. If hypotension occurs, place the patient in the supine position and give physiological saline intravenously if needed. Continue treatment with benazepril once blood pressure and volume have returned to normal.

  


In patients with congestive heart failure, start amlodipine and benazepril hydrochloride therapy under close medical supervision; follow closely for the first 2 weeks of treatment and whenever the dose of the benazepril component is increased or a diuretic is added or its dose increased. 

  


In patients undergoing surgery or during anesthesia with agents that produce hypotension, benazepril will block the angiotensin II formation that could otherwise occur secondary to compensatory renin release. Hypotension that occurs as a result of this mechanism can be corrected by volume expansion.
The detoxification / induction procedure consists of a single day of buprenorphine followed by a washout day and 4 days of ascending oral naltrexone doses. Followed on day 8 by Vivitrol injection. Participants then receive a second injection 4 weeks after the first.
This multi-center study examined the safety and effectiveness of cochlear implantation of children between 9 and 11 months of age. The intended impact was to support practice regarding candidacy assessment and prognostic counseling of pediatric cochlear implant candidates. Data in the clinical chart of children implanted at 9-11 months of age with Cochlear Ltd devices at five cochlear implant centers in the United States and Canada were included in analyses. The study included data from two cohorts implanted with one or two Nucleus devices during the periods of January 1, 2012-December 31, 2017 (Cohort 1, n = 83) or between January 1, 2018 and May 15, 2020 (Cohort 2, n = 50). Major adverse events (requiring another procedure/hospitalization) and minor adverse events (managed with medication alone or underwent an expected course of treatment that did not require surgery or hospitalization) out to 2 years post-implant were monitored and outcomes measured by audiometric thresholds and parent-reports on the IT-MAIS and LittlEARS questionnaires were collected. Results revealed 60 adverse events in 41 children and 227 ears implanted (26%) of which 14 major events occurred in 11 children; all were transitory and resolved. Improved hearing with cochlear implant use was shown in all outcome measures. Findings reveal that the procedure is safe for infants and that they show clear benefits of cochlear implantation including increased audibility and hearing development.
The present invention relates to Chinese medicinal composition which is used for treating external trauma, and is made according to the following weight ratio: 0.5 to 1.5 portion(s) of borneol, 0.5 to 1.5 portion(s) of natural indigo, 0.5 to 1.5 portion(s) of dragon blood, 0.1 to 1.0 portion of artificial charcoal, 10 to 30 portions of charcoal of fir, 25 to 45 portions of talc, and 0.5 to 1.5 portion(s) of cuttlebone. The composition integrates the functions of hemostasis, disinfection, antisepsis and muscle generation, and can be used for comprehensively treating and nursing the wound with excellent curative effects. The medicinal materials of all ingredients are quite universal and cheap. Moreover, the preparation of the medicinal powder is simple and convenient. Simultaneously, all the medicinal materials of the composition have no side effects and no taboo in use. Even pregnant women and children can safely take the medicine.
Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
A system and method for acquiring, hosting and distributing medical images for healthcare professionals. In one illustrative embodiment, the system can include a database for storing private health information split from a medical imaging record. The private health information can be encrypted before being stored within a database. The system can also include a repository for storing at least one anonymized image split from the medical record. The repository can include a number of functionally equivalent servers horizontally scalable to store the at least one anonymized image. The private health information and the at least one anonymized image split from the medical record can be joined at a target node. The private health information can be decrypted on the target node and coupled with the at least one anonymized image to reform the record. The database and the repository can both be provided on cloud services.
Patients with suspected coronary artery disease and those with known coronary artery disease and the suspicion of progressive disease who undergo clinically indicated Coronary Computed Tomography Angiography on the Photon-Counting Detector CT will be enrolled after written consent. All data from the CT scan and potential additional investigations (e.g. invasive coronary angiographies) will be collected. There will be no additional investigations for the purpose of the study. After 1, 2 and 5 years, participants will be asked to answer a health questionaire.
Protein misfolding in the endoplasmic reticulum (ER) of podocytes contributes to the pathogenesis of glomerular diseases. Protein misfolding activates the unfolded protein response (UPR), a compensatory signaling network. We address the role of the UPR and the UPR transducer, inositol-requiring enzyme 1α (IRE1α), in streptozotocin-induced diabetic nephropathy in mice. Diabetes caused progressive albuminuria in control mice that was exacerbated in podocyte-specific IRE1α knockout (KO) mice. Compared to diabetic controls, diabetic IRE1α KO mice showed reductions in podocyte number and synaptopodin. Glomerular ultrastructure was altered only in diabetic IRE1α KO mice; the major changes included widening of podocyte foot processes and glomerular basement membrane. Activation of the UPR and autophagy was evident in diabetic control, but not diabetic IRE1α KO mice. Analysis of human glomerular gene expression in the JuCKD-Glom database demonstrated induction of genes associated with the ER, UPR and autophagy in diabetic nephropathy. Thus, mice with podocyte-specific deletion of IRE1α demonstrate more severe diabetic nephropathy and attenuation of the glomerular UPR and autophagy, implying a protective effect of IRE1α. These results are consistent with data in human diabetic nephropathy and highlight the potential for therapeutically targeting these pathways.
Mammalian central nervous system (CNS) neurons do not regenerate after injury due to the inhibitory environment formed by the glial scar, largely constituted by myelin debris. The use of biomaterials to bridge the lesion area and the creation of an environment favoring axonal regeneration is an appealing approach, currently under investigation. This work aimed at assessing the suitability of three candidate polymers - poly(?-caprolactone), poly(trimethylene carbonate-co- ?-caprolactone) (P(TMC-CL)) (11:89 mol%) and poly(trimethylene carbonate) - with the final goal of using these materials in medicine, namely in the development of conduits to promote spinal cord regeneration. Cortical neurons cultured on P(TMC-CL) in the presence of myelin were able to tame myelin inhibition in comparison with the control condition (glass substrate). This effect was found to be mediated by the glycogen synthase kinase 3p (GSK3p) signaling pathway with impact on the collapsin response mediator protein 4 (CRMP4), suggesting that nanomechanical properties were implicated in this process. The obtained results indicate P(TMC-CL) as a promising material for CNS regenerative applications as it promotes axonal growth, taming myelin inhibition.
Patients with type 2 diabetes often complain about changing blood glucose levels in times of emotional or mental stress, most subject's self-reporting higher blood glucose measurements in stressful conditions. To daily distress in diabetes additional emotional or mental stress can add a further momentum to destabilize glucose levels due to the adrenocortical response with enhancing insulin resistance and decreasing the endogenous insulin secretion. Another physiological link between stress and diabetes might be a higher sensitivity of the hypothalamo-pituitary-adrenal axis, leading to antagonizing effects on insulin actions. A study in type 2 diabetes demonstrated that stressors can destabilize blood glucose levels. Stress levels in diabetes have been shown to have a relationship to diabetic complications. Previous studies of psychological stress in type 1 diabetes have shown no effect of elevated catecholamine levels after short-lived psychological stimuli on glucose levels, but a significantly delayed decrease of glucose concentrations after an acute psychological stress in the postprandial state in association with elevated cortisol levels, showing no change of glucose concentration in the fasting state. This was in contrast to previous data in healthy subjects, showing that low glucose levels before a psychological stress prevented the stress-induced activation of the hypothalamus pituitary adrenal axis, but postprandial higher blood glucose levels induced a large cortisol response. These findings of a different cortisol responses in the fasting or fed status in healthy or absolute insulin deficient subjects could also be relevant for glucose metabolism in subjects with type 2 diabetes.

The effect of an acute psychological stress on glucose concentration may critically depend on whether stress is applied in the fasting or fed state. A different metabolic response to stress depending on food intake could explain different findings in other clinical trials and contribute to understanding glucose responses to stress. The aim of our study was thus to test whether the effect of acute psychological stress on glucose concentrations is different in the fasting compared to the fed state in type 2 diabetes.
BACKGROUND: Skin flap transplantation is used to effectively reconstruct defects of the hand and foot skin and soft tissues. We here investigated the effect of the PF127/bleomycin (BLM) hydrogel on the extracellular matrix (ECM) remodeling of skin flaps and the underlying mechanism, thereby providing a new reference point for personalized flap modification and overcoming abrasion resistance- and stability-associated difficulties.
METHODS: The appropriate PF127/BLM concentration was selected based on the gelation time and drug release curve. Migration assays, scratch assays, and live/dead staining were conducted to verify the effect of PF127/BLM on human skin fibroblasts (HSFs). The effects of PF127/BLM on the ECM were assessed through hematoxylin and eosin and Masson staining. Additionally, we examined the expression of ECM remodeling-related genes and proteins involved in their associated signaling pathway. Finally, the effects of PF127/BLM on organ fibrosis and toxicity to liver and kidney functions were assessed in mice.
RESULTS: A 25% PF127/BLM hydrogel was selected as the study concentration. PF127/BLM augmented HSF chemotaxis and proliferation. Furthermore, PF127/BLM promoted subcutaneous ECM remodeling and fibrosis, increased the flap dermis thickness, and reduced the toxic side effects of BLM on liver/lung fibrosis and liver/kidney function. Additional studies confirmed that the PF127/BLM-mediated regulation of ECM remodeling in skin flaps was associated with TGFβ-Col signaling pathway activation.
CONCLUSION: The PF127/BLM hydrogel promoted subcutaneous ECM remodeling and fibrosis, which aided the construction of personalized flaps through the TGFβ-Col signaling pathway, with decreased hepatic, pulmonary, and renal toxicities.
Patients receive only traditional microsurgical operations in traditional operating theaters or the one-staged hybrid operation theater. No endovascular intervention technique or intraoperative digital subtraction angiography(DSA) will be performed. The DSA will be performed in 3 days after the operation.
At study entry and Week 8, participants will receive the GEO-D03 DNA vaccine administered as 1 mL intramuscularly (IM) in either deltoid. At Weeks 16 and 24, they will receive the MVA/HIV62B vaccine administered as 1 mL IM in either deltoid.
NEW MATERIAL:A monoclonal antibody M206 having the following properties: Reactive strongly to normal human monocytes and weakly to granulocytes, and unreactive to T and B cells. Reactive strongly to leukemic cells derived from acute monocytic leukemia and unreactive to cells, e.g. acute myeloid leukemia. Wholly unreactive to B cellular lines, T cellular lines, etc. in human cellular lines and strongly reactive to macrophage cellular lines. Capable of determining the monocytic groups taking part in the multiplicative response to soluble antigens and discriminating the cellular surface antigen of macrophage cellular lines. PROCESS:A spleen cell of mouse previously immunized with a cell of human cellular line having the characteristic function and form in the monocyte is subjected to the plasmogamy with a cell from a cell of myelomatous cellular line to form a hybridoma, which is then cultivated in a suitable culture fluid (in vitro), and the resultant antibody M206 formed on the supernatant liquid is then recovered to give the aimed antibody.
Inspect parenteral drug products for particulate matter and discoloration prior to use, whenever solution and container permit.

Vasopressin Injection Solution for Dilution, 20 units/mL and 200 units/10 mL (20 units/mL).

Dilute vasopressin injection in 0.9% Sodium Chloride Injection or 5% Dextrose Injection prior to use for intravenous infusion. (See Table 1). Discard unused diluted solution after 18 hours at room temperature or 24 hours under refrigeration.

Table 1 Preparation of diluted solutions
Healthy volunteers will be randomised to one of three cohorts. In each cohort of 8 participants, 6 will receive active drug and 2 will receive placebo. Following safety observation, patients with hypercholesterolaemia will enter a fourth cohort. There will be 15 participants in this cohort.
The present disclosure may provide a method. The method may include obtaining a PET dataset relating to a subject acquired, based on a tracer species in the subject, by a PET device. The PET dataset relating to the subject may be acquired for a time period when the subject moves by moving a couch on which the subject is supported. The time period may include a first time segment and a second time segment. The method may also include determining an activity distribution set of the tracer species in the subject within the time period. The activity distribution set may include a plurality of segment activity distributions. Further, the method may include determining an offset of the couch within the second time segment with respect to the first time segment based on the activity distribution set of the tracer species.
All study participants will undergo a full day (roughly 8 hours) training programme consisting of a pre-test MCQ, a didactic lecture, hands-on training session, a post-test MCQ, and a practical evaluation. They will be randomised to using an A.I. ultrasound machine for teaching.
Part2.Second Stage: randomized, double-blind, sham-injection control study One eye of each participant will undergo sham injection. Sham intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle.